Search

Your search keyword '"Rothley, Jill"' showing total 21 results
Start Over Author "Rothley, Jill"
21 results on '"Rothley, Jill"'

3. Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Author

Jackson, Isaac M., Lee, So Jeong, Sowa, Alexandra R., Rodnick, Melissa E., Bruton, Laura, Clark, Mara, Preshlock, Sean, Rothley, Jill, Rogers, Virginia E., Botti, Leslie E., Henderson, Bradford D., Hockley, Brian G., Torres, Jovany, Raffel, David M., Brooks, Allen F., Frey, Kirk A., Kilbourn, Michael R., Koeppe, Robert A., Shao, Xia, and Scott, Peter J. H.

Published
2020
Full Text
View/download PDF

7. Additional file 1 of Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Author

Jackson, Isaac M., Lee, So Jeong, Sowa, Alexandra R., Rodnick, Melissa E., Bruton, Laura, Clark, Mara, Preshlock, Sean, Rothley, Jill, Rogers, Virginia E., Botti, Leslie E., Henderson, Bradford D., Hockley, Brian G., Jovany Torres, Raffel, David M., Brooks, Allen F., Frey, Kirk A., Kilbourn, Michael R., Koeppe, Robert A., Shao, Xia, and Scott, Peter J. H.

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2020
Full Text
View/download PDF

8. Quantifying cardiac sympathetic denervation: first studies of 18F-fluorohydroxyphenethylguanidines in cardiomyopathy patients.

Author

Raffel, David M., Crawford, Thomas C., Jung, Yong-Woon, Koeppe, Robert A., Gu, Guie, Rothley, Jill, and Frey, Kirk A.

Subjects
DENERVATION, CARDIOMYOPATHIES, INNERVATION of the heart, ISOLATION perfusion, FREIGHT forwarders, SYMPATHECTOMY
Abstract

Purpose: 4-18F-Fluoro-m-hydroxyphenethylguanidine (18F-4F-MHPG) and 3-18F-fluoro-p-hydroxyphenethylguanidine (18F-3F-PHPG) were developed for quantifying regional cardiac sympathetic nerve density using tracer kinetic analysis. The aim of this study was to evaluate their performance in cardiomyopathy patients. Methods: Eight cardiomyopathy patients were scanned with 18F-4F-MHPG and 18F-3F-PHPG. Also, regional resting perfusion was assessed with 13N-ammonia. 18F-4F-MHPG and 18F-3F-PHPG kinetics were analyzed using the Patlak graphical method to obtain Patlak slopes Kp (mL/min/g) as measures of regional nerve density. Patlak slope polar maps were used to evaluate the pattern and extent of cardiac denervation. For comparison, "retention index" (RI) values (mL blood/min/mL tissue) were also calculated and used to assess denervation. Perfusion polar maps were used to estimate the extent of hypoperfusion. Results: Patlak analysis of 18F-4F-MHPG and 18F-3F-PHPG kinetics was successful in all subjects, demonstrating the robustness of this approach in cardiomyopathy patients. Substantial regional denervation was observed in all subjects, ranging from 25 to 74% of the left ventricle. Denervation zones were equal to or larger than the size of corresponding areas of hypoperfusion. The two tracers provided comparable metrics of regional nerve density and the extent of left ventricular denervation. 18F-4F-MHPG exhibited faster liver clearance than 18F-3F-PHPG, reducing spillover from the liver into the inferior wall. 18F-4F-MHPG was also metabolized more consistently in plasma, which may allow application of population-averaged metabolite corrections. Conclusion: The advantages of 18F-4F-MHPG (more rapid liver clearance, more consistent metabolism in plasma) make it the better imaging agent to carry forward into future clinical studies in patients with cardiomyopathy. Trial registration: Registered at the ClinicalTrials.gov website (NCT02669563). URL:https://clinicaltrials.gov/ct2/show/NCT02669563 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

10. Initial clinical experience of N13-ammonia myocardial perfusion PET/CT using a compact superconducting production system

Author

Pieper, Justin, primary, Patel, Vaiibhav N., additional, Escolero, Sylvia, additional, Nelson, Jacob R., additional, Poitrasson-Rivière, Alexis, additional, Shreves, Christopher K., additional, Freiburger, Nick, additional, Hubers, David, additional, Rothley, Jill, additional, Corbett, James R., additional, Oliverio, Joseph, additional, Ficaro, Edward P., additional, Weinberg, Richard L., additional, and Murthy, Venkatesh L., additional

Published
2019
Full Text
View/download PDF

14. Anxiety and cerebral cortical metabolism in normal persons

Author

Giordani, Bruno, primary, Boivin, Michael J., additional, Berent, Stanley, additional, Betley, Annette T., additional, Koeppe, Robert A., additional, Rothley, Jill M., additional, Modell, Jack G., additional, Hichwa, Richard D., additional, and Kuhl, David E., additional

Published
1990
Full Text
View/download PDF

15. Neuronal mapping of the heart with 6-[18F]fluorometaraminol

Author

Wieland, Donald M., primary, Rosenspire, Karen C., additional, Hutchins, Gary D., additional, Van Dort, Marcian, additional, Rothley, Jill M., additional, Mislankar, Suresh G., additional, Lee, Helen T., additional, Massin, Christopher C., additional, and Gildersleeve, David L., additional

Published
1990
Full Text
View/download PDF

18. Normal Caudate Glucose Metabolism in Persons at Risk for Huntington's Disease

Author

Young, Anne B., Penney, John B., Starosta-Rubinstein, Simon, Markel, Dorene, Berent, Stanley, Rothley, Jill, Betley, Annette, and Hichwa, Richard

Abstract

• Glucose metabolism was examined by positron emission tomographic scanning with18F-2-fluoro-2-deoxy-d-glucose in 29 persons at risk for Huntington's disease (HD), 28 age-matched controls, nine patients with stage I, and eight patients with stage II symptomatic HD. Absolute caudate metabolic rates and normalized indexes of caudate metabolism for at-risk persons were normal compared with controls. No at-risk person had caudate indexes outside two SDs of the controls' mean. Caudate metabolism in the earliest HD cases was significantly reduced compared with controls and atrisk persons, but within the 99% confidence levels of both groups. Stage II patients had caudate measures that were significantly depressed compared with those of stage I HD patients. Measurement of caudate glucose hypometabolism is unlikely to be sufficiently sensitive to serve as a presymptomatic marker of heterozygote status, although it will provide a sensitive marker for progressive caudate dysfunction in HD.

Published
1987
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results